Taking advantage of a long history of collaboration, the Catalan Institute of Finance (ICF) once again invests in Invivo Partners. On this occasion, the public promotion bank of the Generalitat invests 8 million euros expandable up to 10 million in Invivo Ventures III, an advanced therapies fund. This alliance underscores the ICF's enduring commitment to the growth of the life sciences sector. With a €100 million goal, the fund aims to transform healthcare through cutting-edge therapies and technologies, including cell therapy, synthetic biology and artificial intelligence.
The origin of the partnership between ICF and Invivo Partners can be traced to the first fund, Healthequity, where the ICF already played an important role that it maintained with the second, Invivo Ventures and now consolidates in this third fund. This growing support reflects the shared commitment to catalyze the life sciences and create a resilient ecosystem for healthcare innovation in Catalonia and increase investment. This strategic effort also aligns Invivo's investment thesis with the ICF's economic development goals, driving Catalonia to the forefront of the global life sciences field, and strengthening the ICF as a tool for investment in Catalan innovation companies.
The Invivo network, particularly robust within Catalonia, exemplifies the emergence of the region as a biotechnology center recognized for its excellence in research. Invivo's expansion beyond Catalonia, interacting with projects and Technology Transfer Offices throughout Spain and notable European institutions, testifies to the growing influence and dedication to finding transformative scientific discoveries.
Barcelona has stood out as a leading centre for health research and innovation in Europe. The region shows a consistent pattern of entrepreneurial activity, with an average start-up rate of 1 to 1.5 startups and/or spin-offs per week, indicative of a vibrant culture of start-ups and spin-offs. At the same time, a notable increase has been observed in the establishment of new investment entities, both specialised and diversified, aimed at fostering ecosystem growth.
The role of Invivo in the development of numerous spin-offs in Catalonia, including Peptomyc of VHIO, Minoryx of UB and OneChain of IJC, is a testament to the strong connections between Invivo and the academic and research community.
Vanessa Servera i Planas, CEO of the ICF, explains that "one of the priorities of public promotion banks is to grow strategic areas of the country, such as research and research in life sciences, which have a very high transformative power in people's quality of life. Investing in life sciences means investing in life, in the survival of sick people and also in strengthening the business fabric with jobs, companies and cutting-edge research. And here the ICF wants to bet more."
Luis Pareras, Managing Partner of Invivo, explains that "The investment of the Catalan Institute of Finance in Invivo Ventures III marks a key moment in our mission to lead transformation in the field of advanced therapies. The ICF's continued trust and support from our first fund reflect the strength of our shared vision: to make Catalonia a global benchmark in life sciences, and to strengthen the economy and research around us. This new fund will allow us to accelerate the development of revolutionary therapies, demonstrating our commitment to creating a healthier future for all."
About the ICF
The Catalan Institute of Finance (ICF) is the public financial entity of the Government of Catalonia and its main mission is to promote the growth of companies and other entities. It finances relevant and transformative projects through loans and capital, with special emphasis on the ecological transition, reindustrialization and social housing. The ICF usually complements loans from the private financial sector, offering long repayment periods to facilitate debt repayment.
Since 2014, it has been a member of the European Association of Public Banks (EAPB), which brings together most of the banks and public financial institutions operating in Europe.
About Invivo Partners
Invivo Partners is a Spanish venture capital firm that invests in early-stage life sciences companies at the intersection of advanced therapies, synthetic biology and artificial intelligence. It manages two funds supported by a majority of private investors and several institutional investors such as the European Investment Fund (EIF), Fond-ICO Global, the Catalan Institute of Finance, the Valencian Institute of Finance and Barcelona City Council.
cloud technology axon
This acquisition signifies Meridia's entry into one of the most esteem...
